<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194986</url>
  </required_header>
  <id_info>
    <org_study_id>D3030C00003</org_study_id>
    <secondary_id>2009-010702-11</secondary_id>
    <nct_id>NCT01194986</nct_id>
  </id_info>
  <brief_title>Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration</brief_title>
  <official_title>An Open-label Positron Emission Tomography Study to Evaluate Use of Histamine H3 Receptor Radioligand [11C]AZ12807110 and to Determine Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate features of radioligand [11C]AZ12807110 and how
      much AZD5213 displaces radioligand from histamine receptors when given together.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution volume (VT)</measure>
    <time_frame>Venous blood samples for determination of concentrations of AZD5213 in plasma will be taken on many occasions from pre-dose until 48 h post-dose. Single PET measurement will take maximum 2 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimation of the plasma concentration resulting in 50% receptor occupancy (Ki, pl).</measure>
    <time_frame>Venous blood samples for determination of concentrations of AZD5213 in plasma will be taken on many occasions from pre-dose until 48 h post-dose.</time_frame>
    <description>Each healthy volunteer in the main panel will complete 3 PET measurements using radioligand; one at baseline and 2 after treatment with AZD5213.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Collected from Day 1 to follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs (body temperature, BP and pulse)</measure>
    <time_frame>Measured at screening, study days -1 to day 3 and at follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Brain Distribution of [11C]AZ12807110 and AZD5213</condition>
  <arm_group>
    <arm_group_label>Pilot panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[11C]AZ12807110 distribution and kinetics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Histamine receptor occupancy reached by AZD5213</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C]AZ12807110</intervention_name>
    <description>Radioligand</description>
    <arm_group_label>Pilot panel</arm_group_label>
    <arm_group_label>Main panel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5213</intervention_name>
    <arm_group_label>Main panel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female volunteers between 20 to 45 years with suitable veins for
             cannulation or repeated venipuncture (pilot panel)

          -  Female must be of non-child bearing potential (pilot panel)

          -  BMI between 18 to 30 30 kg/m2

          -  Normal MRI scan

          -  Provision of signed, written and dated informed consent

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  History or presence of gastrointestinal, hepatic or renal disease

          -  Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms or family history of long QT syndrome

          -  History of severe allergy or hypersensitivity or ongoing allergy or hypersensitivity

          -  Healthy volunteer suffers from claustrophobia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn Paulsson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kühn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB, Uppsala</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1314&amp;filename=D3030C00003_Clinical_Study_Report_Synopsis.pdf</url>
    <description>D3030C00003 Clinical Study Report Synopsis</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Receptor binding</keyword>
  <keyword>Histamine H3 receptor</keyword>
  <keyword>binding</keyword>
  <keyword>radioligand</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

